Leqvio Manufacturer Copay Program: How to Get Inclisiran Cheaper in 2026

What Is Leqvio and Why Are Women Asking About It?

Leqvio (inclisiran) is a small interfering RNA (siRNA) therapy that lowers LDL cholesterol by silencing the gene that produces PCSK9 in the liver. It does not work like a statin or a monoclonal antibody. A clinician injects it in-office twice a year (after three loading doses), which means you are not managing a daily pill or self-injecting weekly.

Women are asking about it because cardiovascular disease is the leading cause of death in American women, responsible for 1 in 5 female deaths according to the CDC. After menopause, LDL-C typically rises sharply as estrogen's protective effect on lipid metabolism declines, and statin intolerance is reported more frequently by women than men. When statins and ezetimibe are not enough, or when side effects make them unworkable, a twice-yearly injection becomes genuinely appealing. The problem is the price.

What Inclisiran Actually Costs Without Help

The list price of Leqvio is well above what most people can absorb. The average cash pay price sits at approximately $540 per dose, though this figure varies by pharmacy and institution and can run considerably higher depending on your location and the facility fee attached to in-office administration. Because Leqvio is typically administered in a physician's office rather than picked up at a retail pharmacy, you may face both a drug cost and a separate administration fee that insurance handles differently. That dual billing structure is something women frequently do not anticipate.

Who Is Approved to Use It

The FDA approved inclisiran in December 2021 for adults with:

• Atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on maximally tolerated statin therapy
• Heterozygous familial hypercholesterolemia (HeFH)

It is not currently FDA-approved for primary prevention alone, which affects insurance coverage decisions significantly.

The Novartis Manufacturer Copay Program: What It Covers

Novartis operates a patient support program for Leqvio. The specific copay assistance program for commercially insured patients can reduce your out-of-pocket cost, sometimes to as little as zero dollars per dose depending on your plan and eligibility.

Critical caveat: Manufacturer copay programs change their terms, eligibility thresholds, income limits, and maximum benefit amounts frequently. Every figure you read anywhere, including here, should be verified directly with Novartis before you make any financial decisions. The program contact is the Novartis Patient Assistance Foundation at 1-800-282-7630.

Who Qualifies for Commercial Copay Assistance

To access the commercial copay card, you generally need to meet all of these criteria:

• You have commercial (private) insurance, including insurance purchased through the ACA marketplace
• Your insurance covers Leqvio (even partially)
• You are not enrolled in a government-funded program such as Medicare, Medicaid, TRICARE, or any state or federal pharmacy assistance program
• You are a US resident
• You meet any income or benefit cap the program has set at the time you apply

If you have Medicare Part D, you are typically excluded from manufacturer copay programs due to federal anti-kickback provisions. This is a meaningful gap because many postmenopausal women who need Leqvio most are on Medicare. See the Medicare-specific section below.

How to Enroll

1. Ask your prescribing cardiologist or internist to initiate enrollment through the Novartis Specialty Hub, or call 1-800-282-7630 directly.
2. Have your insurance card and prescription information ready.
3. The hub conducts a benefits investigation to confirm what your plan will cover and what assistance you qualify for.
4. If approved, the copay card is applied at the time of administration, typically at your physician's office.

The enrollment process can take several days to a few weeks. If you have a time-sensitive cardiovascular event history driving the prescription, ask your physician's office to flag the case as urgent.

Insurance Coverage for Leqvio: What to Expect

Insurance coverage for inclisiran varies considerably by payer, plan tier, and the prior authorization criteria your insurer uses.

Prior Authorization Is Almost Universal

Nearly every commercial insurer requires prior authorization before approving Leqvio. Your physician will need to document:

• Your most recent LDL-C level (many plans require LDL-C ≥70 mg/dL for ASCVD patients despite maximally tolerated statin therapy, or ≥100 mg/dL for HeFH)
• Evidence of maximally tolerated statin therapy or documented statin intolerance
• Your cardiovascular diagnosis (ASCVD or HeFH)
• Often, a trial and failure of or contraindication to ezetimibe

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction provides the evidence base that physicians use to argue medical necessity for PCSK9-lowering therapies. Citing this guideline explicitly in the prior authorization letter can strengthen the case.

Step Therapy: The Ezetimibe Hurdle

Many plans require you to try and fail ezetimibe before they will approve a PCSK9-directed therapy. Ezetimibe is inexpensive and generally well-tolerated, so this step is often reasonable. If you have already tried it or have a reason to avoid it, document that clearly with your physician before submitting the prior authorization.

Specialty Pharmacy vs. Medical Benefit

Leqvio sits in an unusual position: it may be billed under your pharmacy benefit (Part D for Medicare patients) or under your medical benefit (Part B for Medicare patients who receive it in a physician's office). For commercial patients, this distinction determines which formulary tier applies and which deductible counts. Ask your insurer explicitly which benefit covers inclisiran before assuming you know your cost-sharing.

If You Have Medicare: Your Real Options

The manufacturer copay card does not apply to Medicare beneficiaries. This is a significant issue because postmenopausal cardiovascular risk is highest in women over 65, precisely the population most likely to be on Medicare.

Medicare Part B Coverage

When Leqvio is administered in a physician's office, it may be billed under Medicare Part B as a physician-administered drug. Part B coverage typically involves 20% coinsurance after your deductible, which at current list pricing could still be several hundred dollars per dose. A Medicare supplement (Medigap) policy or Medicare Advantage plan may reduce that coinsurance substantially.

Medicare Part D Coverage

If your plan covers Leqvio under Part D, your cost will depend on your plan's formulary tier and the phase of the Part D benefit you are in. The Inflation Reduction Act introduced a $2,000 annual out-of-pocket cap for Part D enrollees beginning in 2025, which meaningfully limits total yearly exposure for high-cost drugs.

Novartis Patient Assistance Foundation

For Medicare patients who meet income criteria, the Novartis Patient Assistance Foundation may provide the drug at no cost. Income thresholds change annually, so verify current eligibility directly.

State Pharmaceutical Assistance Programs (SPAPs)

Several states operate programs that wrap around Medicare Part D to reduce drug costs for qualifying low-income seniors. Your State Health Insurance Assistance Program (SHIP) counselor can help you identify what exists in your state. Find your local SHIP through benefits.gov or the Medicare helpline at 1-800-MEDICARE.

Women-Specific Considerations: Life Stage Shapes Your Risk and Your Access Strategy

Cardiovascular risk is not the same across a woman's life. When you are thinking about Leqvio, your hormonal and reproductive status changes both the clinical picture and the practical considerations around access.

Reproductive Years (Ages 18-40)

LDL-C is typically lower during the reproductive years due to the effects of endogenous estrogen on hepatic LDL receptor upregulation. Leqvio is rarely indicated in this life stage unless you have HeFH or another specific high-risk condition. If it is prescribed, contraception planning is mandatory. See the pregnancy section below.

PCOS and Metabolic Dyslipidemia

Women with polycystic ovary syndrome (PCOS) carry a disproportionate burden of dyslipidemia, particularly elevated LDL-C and triglycerides in combination with insulin resistance. The Endocrine Society PCOS Guidelines recommend cardiovascular risk assessment as part of routine PCOS management. If your LDL-C remains elevated despite lifestyle changes and statin therapy, the conversation about PCSK9 inhibition is legitimate even in your 30s. The access pathways are the same; you will need a documented cardiovascular risk profile or HeFH diagnosis to clear insurance prior authorization.

Perimenopause (Typically Ages 45-55)

This is the stage where LDL-C commonly rises and becomes harder to manage. The hormonal transition drives changes in hepatic lipid metabolism as estrogen levels fluctuate and decline. A study published in JAMA Internal Medicine found that LDL-C increases significantly across the menopause transition even in women without prior dyslipidemia. If your cardiologist identifies high-risk ASCVD or HeFH during perimenopause and statins are insufficient or intolerable, inclisiran access becomes a practical question worth addressing now, before you move to Medicare.

Timing matters here. If you are still on commercial insurance through an employer, the copay assistance program is available to you in a way it will not be once you shift to Medicare.

Postmenopause

This is when cardiovascular risk climbs most steeply. Estrogen loss accelerates atherogenesis, and women who maintained low-risk lipid profiles during their reproductive years may see LDL-C climb into ranges that require pharmacological intervention. The ORION-11 trial, which evaluated inclisiran in patients with ASCVD or ASCVD risk equivalents, included a meaningful proportion of women, though women remain underrepresented in cardiovascular outcomes trials generally. (See the evidence gap note below.)

The Evidence Gap: What the Data in Women Actually Shows

Women have been systematically underrepresented in cardiovascular lipid trials. In the ORION program, which generated the evidence base for inclisiran's approval, women made up approximately 28-32% of enrolled participants across the major trials. The ORION-9 trial, which studied HeFH patients, had a somewhat higher female representation because HeFH affects women and men roughly equally.

What this means in practice:

• LDL-C reduction efficacy data is largely extrapolated from male-dominated cohorts. The observed 50-52% LDL-C reduction in ORION-11 is applied to female patients, but sex-stratified subgroup analyses have not been published as primary endpoints.
• Pharmacokinetic data in women specifically (including the effect of lower body weight, different adipose distribution, or hormonal status on siRNA distribution) is not well characterized in the published literature.
• Sex-specific adverse event profiles are not reported separately by Novartis in the key trial publications.

This is not a reason to avoid inclisiran if you need it. It is a reason to ask your physician explicitly: "What does the data in women show?" and to expect an honest answer that includes the word "extrapolated."

As The Menopause Society states in its 2023 position statement on cardiovascular disease: "Lipid-lowering therapy should not be withheld from postmenopausal women on the basis of sex alone, and treatment targets should mirror those applied in high-risk male populations."

Pregnancy, Lactation, and Contraception: Non-Negotiable Safety Information

Leqvio is contraindicated in pregnancy. This must be stated plainly because it shapes every conversation about access for women of reproductive age.

Pregnancy

There are no adequate human data on inclisiran use in pregnancy. Animal reproduction studies showed fetal harm at exposures below the human therapeutic dose. The FDA prescribing information advises that Leqvio should be discontinued before a planned pregnancy. Because inclisiran has a long pharmacological duration (its LDL-C-lowering effect persists for approximately 6 months after a dose), the timing of discontinuation relative to conception needs to be discussed with your physician well in advance.

LDL-C is not a lipid you should be aggressively lowering during pregnancy. Cholesterol is a substrate for placental progesterone synthesis and fetal development. There is no safe threshold of LDL reduction in pregnancy established for any PCSK9-directed therapy.

If you become pregnant while on Leqvio, contact your physician immediately. Report the exposure to the Novartis pregnancy registry at 1-888-NOW-NOVA (1-888-669-6682).

Contraception Requirements

If you are of reproductive potential and your physician prescribes inclisiran, you need reliable contraception. There is no formally defined washout period published in the labeling, but given the 6-month duration of effect and the absence of reversal options, most clinicians advise waiting at least one full dosing cycle (6 months) after the last injection before attempting conception. Confirm this timeline with your prescribing physician and your reproductive endocrinologist if you are planning a pregnancy.

Lactation

It is not known whether inclisiran is present in human breast milk. No human lactation data exist. Because the potential for harm to a breastfed infant cannot be excluded, the FDA prescribing information advises that women should not breastfeed during treatment with Leqvio. This is a postpartum-stage consideration: if you are breastfeeding and a cardiologist raises the question of inclisiran, weigh the duration of breastfeeding against the urgency of LDL-C lowering in conversation with both your cardiologist and your OB or midwife.

Who This Drug Is Right For (And Who It Is Not)

Right for You If:

• You have a confirmed ASCVD diagnosis or HeFH
• Your LDL-C remains above your cardiologist's target despite maximally tolerated statin therapy plus ezetimibe
• You have documented statin intolerance and your LDL-C is high enough to warrant aggressive intervention
• You are postmenopausal with established cardiovascular disease and are on commercial insurance or Medicare with supplemental coverage
• You are perimenopausal with HeFH and your employer-based commercial insurance makes the copay program accessible now

Not Right for You If:

• You are pregnant or planning pregnancy in the next 6-12 months
• You are breastfeeding
• You are seeking primary prevention only without an ASCVD or HeFH diagnosis (coverage is unlikely and the clinical evidence base is thinner)
• Your LDL-C is well-controlled on current therapy and the primary driver is cost reduction on existing medications
• You are unwilling or unable to come to a clinic for twice-yearly injections (some women prefer self-administered options such as evolocumab or alirocumab for this reason)

Alternatives Worth Knowing

If inclisiran access is blocked by cost, insurance denial, or your life stage, these are the other tools in the PCSK9 space:

• Evolocumab (Repatha): A monthly or biweekly self-injected monoclonal antibody with a similar LDL-C lowering magnitude (~60%). Amgen's copay program is similarly structured and excludes Medicare. FDA label and trial data are available here.
• Alirocumab (Praluent): Biweekly or monthly self-injection. Sanofi/Regeneron's copay program follows comparable eligibility rules.
• Bempedoic acid (Nexletol): An oral option for statin-intolerant patients that lowers LDL-C by approximately 18% in the CLEAR Outcomes trial. Less potent but oral and self-managed.
• Ezetimibe: Inexpensive generic, oral, well-tolerated, and often available for under $10 per month with a GoodRx coupon. If you have not yet tried it, most insurers will require it before approving Leqvio anyway.

The "compounded average" for inclisiran is listed as $0 because inclisiran is not currently available as a compounded preparation in the United States. Its siRNA mechanism requires proprietary synthesis and formulation. Any offer of compounded inclisiran should be treated with extreme skepticism and reported to the FDA.

Practical Steps to Take This Week

This is the sequence that moves fastest for most patients navigating Leqvio access:

1. Get your LDL-C documented in writing. Your prescribing physician needs a recent lab value as the anchor for prior authorization.
2. Ask your physician's office to run a benefits investigation through the Novartis Specialty Hub before you commit to a treatment plan. This tells you what your plan will actually cover.
3. Apply for the Novartis copay program at the same time as the prior authorization. The two processes run in parallel. Call 1-800-282-7630 or visit novartis.com/us-en/patients-caregivers.
4. If you have Medicare, ask your SHIP counselor or a licensed Medicare broker to review your current plan's formulary and whether a switch at the next open enrollment period would improve your inclisiran coverage.
5. If you are denied, ask your physician to submit a peer-to-peer review with the insurance medical director. Denial rates drop substantially after physician-to-physician review for medically appropriate PCSK9 therapy.
6. If you are of reproductive age, have the contraception and pregnancy-planning conversation with your physician before your first dose, not after.

Novartis program terms are subject to change at any time. Verify all details directly with the manufacturer before making treatment or financial decisions. The program number to call is 1-800-282-7630.